This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lane, H. A.
Right arrow Articles by Hynes, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lane, H. A.
Right arrow Articles by Hynes, N. E.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, May 2000, p. 3210-3223, Vol. 20, No. 9
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

Heidi A. Lane,* Iwan Beuvink, Andrea B. Motoyama, John M. Daly, Richard M. Neve, and Nancy E. Hynes

Friedrich Miescher Institute, CH-4002 Basel, Switzerland

Received 9 August 1999/Returned for modification 1 November 1999/Accepted 3 February 2000

Overexpression of the ErbB2 receptor, a major component of the ErbB receptor signaling network, contributes to the development of a number of human cancers. ErbB2 presents itself, therefore, as a target for antibody-mediated therapies. In this respect, anti-ErbB2 monoclonal antibody 4D5 specifically inhibits the growth of tumor cells overexpressing ErbB2. We have analyzed the effect of 4D5-mediated ErbB2 inhibition on the cell cycle of the breast tumor cell line BT474. 4D5 treatment of BT474 cells resulted in a G1 arrest, preceded by rapid dephosphorylation of ErbB2, inhibition of cytoplasmic signal transduction pathways, accumulation of the cyclin-dependent kinase inhibitor p27Kip1, and inactivation of cyclin-Cdk2 complexes. Time courses demonstrated that 4D5 treatment redirects p27Kip1 onto Cdk2 complexes, an event preceding increased p27Kip1 expression; this correlates with the downregulation of c-Myc and D-type cyclins (proteins involved in p27Kip1 sequestration) and the loss of p27Kip1 from Cdk4 complexes. Similar events were observed in ErbB2-overexpressing SKBR3 cells, which exhibited reduced proliferation in response to 4D5 treatment. Here, p27Kip1 redistribution resulted in partial Cdk2 inactivation, consistent with a G1 accumulation. Moreover, p27Kip1 protein levels remained constant. Antisense-mediated inhibition of p27Kip1 expression in 4D5-treated BT474 cells further demonstrated that in the absence of p27Kip1 accumulation, p27Kip1 redirection onto Cdk2 complexes is sufficient to inactivate Cdk2 and establish the G1 block. These data suggest that ErbB2 overexpression leads to potentiation of cyclin E-Cdk2 activity through regulation of p27Kip1 sequestration proteins, thus deregulating the G1/S transition. Moreover, through comparison with an ErbB2-overexpressing cell line insensitive to 4D5 treatment, we demonstrate the specificity of these cell cycle events and show that ErbB2 overexpression alone is insufficient to determine the cellular response to receptor inhibition.

* Corresponding author. Mailing address: Friedrich Miescher Institute, R-1066.210, Maulbeerstrasse 66, CH-4058 Basel, Switzerland. Phone: 41 61 697 8089; Fax: 41 61 697 3976. E-mail: hlane{at}fmi.ch.

Molecular and Cellular Biology, May 2000, p. 3210-3223, Vol. 20, No. 9
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Andrei, A., Kendziorski, C. (2009). An efficient method for identifying statistical interactors in gene association networks. Biostatistics 10: 706-718 [Abstract] [Full Text]  
  • Meira, M., Masson, R., Stagljar, I., Lienhard, S., Maurer, F., Boulay, A., Hynes, N. E. (2009). Memo is a cofilin-interacting protein that influences PLC{gamma}1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration. J. Cell Sci. 122: 787-797 [Abstract] [Full Text]  
  • Esparis-Ogando, A., Ocana, A., Rodriguez-Barrueco, R., Ferreira, L., Borges, J., Pandiella, A. (2008). Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 19: 1860-1869 [Abstract] [Full Text]  
  • Fereshteh, M. P., Tilli, M. T., Kim, S. E., Xu, J., O'Malley, B. W., Wellstein, A., Furth, P. A., Riegel, A. T. (2008). The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice. Cancer Res. 68: 3697-3706 [Abstract] [Full Text]  
  • Hynes, N. E (2008). ErbB Receptors in Cancer: HER2/ErbB2 as a Therapeutic Target. aacredbook 2008: 123-130 [Abstract] [Full Text]  
  • Ocana, A., Pandiella, A. (2008). Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options. Clin. Cancer Res. 14: 961-970 [Abstract] [Full Text]  
  • Le, X.-F., Arachchige-Don, A. S., Mao, W., Horne, M. C., Bast, R. C. Jr. (2007). Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Molecular Cancer Therapeutics 6: 2843-2857 [Abstract] [Full Text]  
  • Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., Arteaga, C. L. (2007). Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. Clin. Cancer Res. 13: 4909-4919 [Abstract] [Full Text]  
  • Koziczak-Holbro, M., Joyce, C., Gluck, A., Kinzel, B., Muller, M., Tschopp, C., Mathison, J. C., Davis, C. N., Gram, H. (2007). IRAK-4 Kinase Activity Is Required for Interleukin-1 (IL-1) Receptor- and Toll-like Receptor 7-mediated Signaling and Gene Expression. J. Biol. Chem. 282: 13552-13560 [Abstract] [Full Text]  
  • Montero, J. C., Rodriguez-Barrueco, R., Yuste, L., Juanes, P. P., Borges, J., Esparis-Ogando, A., Pandiella, A. (2007). The Extracellular Linker of pro-Neuregulin-{alpha}2c Is Required for Efficient Sorting and Juxtacrine Function. Mol. Biol. Cell 18: 380-393 [Abstract] [Full Text]  
  • Furuuchi, K., Berezov, A., Kumagai, T., Greene, M. I. (2007). Targeted Antireceptor Therapy with Monoclonal Antibodies Leads to the Formation of Inactivated Tetrameric Forms of ErbB Receptors. J. Immunol. 178: 1021-1029 [Abstract] [Full Text]  
  • Porter, P. L., Barlow, W. E., Yeh, I-T., Lin, M. G., Yuan, X. P., Donato, E., Sledge, G. W., Shapiro, C. L., Ingle, J. N., Haskell, C. M., Albain, K. S., Roberts, J. M., Livingston, R. B., Hayes, D. F. (2006). p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy. JNCI J Natl Cancer Inst 98: 1723-1731 [Abstract] [Full Text]  
  • Cardoso, F., Durbecq, V., Laes, J.-F., Badran, B., Lagneaux, L., Bex, F., Desmedt, C., Willard-Gallo, K., Ross, J. S., Burny, A., Piccart, M., Sotiriou, C. (2006). Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Molecular Cancer Therapeutics 5: 3042-3051 [Abstract] [Full Text]  
  • Menendez, J. A., Mehmi, I., Lupu, R. (2006). Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression. JCO 24: 3735-3746 [Abstract] [Full Text]  
  • Arteaga, C. L. (2006). Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors?. JCO 24: 3722-3725 [Full Text]  
  • Kim, W. E., Serrero, G. (2006). PC Cell-Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells.. Clin. Cancer Res. 12: 4192-4199 [Abstract] [Full Text]  
  • Yuste, L., Montero, J. C., Esparis-Ogando, A., Pandiella, A. (2005). Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Res. 65: 6801-6810 [Abstract] [Full Text]  
  • Hu, Y. P., Venkateswarlu, S., Sergina, N., Howell, G., Clair, P. St., Humphrey, L. E., Li, W., Hauser, J., Zborowska, E., Willson, J. K. V., Brattain, M. G. (2005). Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells. J. Biol. Chem. 280: 27383-27392 [Abstract] [Full Text]  
  • Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., Lane, H. A. (2005). Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer. Clin. Cancer Res. 11: 5319-5328 [Abstract] [Full Text]  
  • Bazley, L A, Gullick, W J (2005). The epidermal growth factor receptor family. Endocr Relat Cancer 12: S17-S27 [Abstract] [Full Text]  
  • Trost, T. M., Lausch, E. U., Fees, S. A., Schmitt, S., Enklaar, T., Reutzel, D., Brixel, L. R., Schmidtke, P., Maringer, M., Schiffer, I. B., Heimerdinger, C. K., Hengstler, J. G., Fritz, G., Bockamp, E. O., Prawitt, D., Zabel, B. U., Spangenberg, C. (2005). Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells. Cancer Res. 65: 840-849 [Abstract] [Full Text]  
  • Le, X.-F., Lammayot, A., Gold, D., Lu, Y., Mao, W., Chang, T., Patel, A., Mills, G. B., Bast, R. C. Jr. (2005). Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. J. Biol. Chem. 280: 2092-2104 [Abstract] [Full Text]  
  • Chu, I., Blackwell, K., Chen, S., Slingerland, J. (2005). The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer. Cancer Res. 65: 18-25 [Abstract] [Full Text]  
  • Koziczak, M., Hynes, N. E. (2004). Cooperation between Fibroblast Growth Factor Receptor-4 and ErbB2 in Regulation of Cyclin D1 Translation. J. Biol. Chem. 279: 50004-50011 [Abstract] [Full Text]  
  • Theodoropoulou, M, Arzberger, T, Gruebler, Y, Jaffrain-Rea, M L, Schlegel, J, Schaaf, L, Petrangeli, E, Losa, M, Stalla, G K, Pagotto, U (2004). Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183: 385-394 [Abstract] [Full Text]  
  • Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., Lupu, R. (2004). Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. USA 101: 10715-10720 [Abstract] [Full Text]  
  • Miller, K. D. (2004). The Role of ErbB Inhibitors in Trastuzumab Resistance. The Oncologist 9: 16-19 [Abstract] [Full Text]  
  • Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., Esteva, F. J. (2004). P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells. Cancer Res. 64: 3981-3986 [Abstract] [Full Text]  
  • Warburton, C., Dragowska, W. H., Gelmon, K., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A. E., Bally, M. B. (2004). Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. Clin. Cancer Res. 10: 2512-2524 [Abstract] [Full Text]  
  • Yang, C., Ionescu-Tiba, V., Burns, K., Gadd, M., Zukerberg, L., Louis, D. N., Sgroi, D., Schmidt, E. V. (2004). The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer. Am. J. Pathol. 164: 1031-1038 [Abstract] [Full Text]  
  • Argiris, A., Wang, C.-X., Whalen, S. G., DiGiovanna, M. P. (2004). Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). Clin. Cancer Res. 10: 1409-1420 [Abstract] [Full Text]  
  • Boulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O'Reilly, T., Stolz, B., Marti, A., Thomas, G., Lane, H. A. (2004). Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells. Cancer Res. 64: 252-261 [Abstract] [Full Text]  
  • Nahta, R., Esteva, F. J. (2003). HER-2-Targeted Therapy: Lessons Learned and Future Directions. Clin. Cancer Res. 9: 5078-5084 [Abstract] [Full Text]  
  • Suarez, Y., Gonzalez, L., Cuadrado, A., Berciano, M., Lafarga, M., Munoz, A. (2003). Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Molecular Cancer Therapeutics 2: 863-872 [Abstract] [Full Text]  
  • Barbacci, E. G., Pustilnik, L. R., Rossi, A. M. K., Emerson, E., Miller, P. E., Boscoe, B. P., Cox, E. D., Iwata, K. K., Jani, J. P., Provoncha, K., Kath, J. C., Liu, Z., Moyer, J. D. (2003). The Biological and Biochemical Effects of CP-654577, a Selective erbB2 Kinase Inhibitor, on Human Breast Cancer Cells. Cancer Res. 63: 4450-4459 [Abstract] [Full Text]  
  • Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F. III, Hynes, N. E. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100: 8933-8938 [Abstract] [Full Text]  
  • Nahta, R., Trent, S., Yang, C., Schmidt, E. V. (2003). Epidermal Growth Factor Receptor Expression Is a Candidate Target of the Synergistic Combination of Trastuzumab and Flavopiridol in Breast Cancer. Cancer Res. 63: 3626-3631 [Abstract] [Full Text]  
  • Le, X.-F., Claret, F.-X., Lammayot, A., Tian, L., Deshpande, D., LaPushin, R., Tari, A. M., Bast, R. C. Jr. (2003). The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition. J. Biol. Chem. 278: 23441-23450 [Abstract] [Full Text]  
  • Arteaga, C. L., Baselga, J. (2003). Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice. Clin. Cancer Res. 9: 1579-1589 [Full Text]  
  • Dakappagari, N. K., Pyles, J., Parihar, R., Carson, W. E., Young, D. C., Kaumaya, P. T. P. (2003). A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses. J. Immunol. 170: 4242-4253 [Abstract] [Full Text]  
  • Jeruss, J. S., Liu, N. X., Chung, Y., Magrane, G., Waldman, F., Edgerton, S., Yang, X., Thor, A. D. (2003). Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis 24: 659-664 [Abstract] [Full Text]  
  • Hernan, R., Fasheh, R., Calabrese, C., Frank, A. J., Maclean, K. H., Allard, D., Barraclough, R., Gilbertson, R. J. (2003). ERBB2 Up-Regulates S100A4 and Several other Prometastatic Genes in Medulloblastoma. Cancer Res. 63: 140-148 [Abstract] [Full Text]  
  • Lee, S., Yang, W., Lan, K.-H., Sellappan, S., Klos, K., Hortobagyi, G., Hung, M.-C., Yu, D. (2002). Enhanced Sensitization to Taxol-induced Apoptosis by Herceptin Pretreatment in ErbB2-overexpressing Breast Cancer Cells. Cancer Res. 62: 5703-5710 [Abstract] [Full Text]  
  • Mellinghoff, I. K., Tran, C., Sawyers, C. L. (2002). Growth Inhibitory Effects of the Dual ErbB1/ErbB2 Tyrosine Kinase Inhibitor PKI-166 on Human Prostate Cancer Xenografts. Cancer Res. 62: 5254-5259 [Abstract] [Full Text]  
  • Fujita, N., Sato, S., Katayama, K., Tsuruo, T. (2002). Akt-dependent Phosphorylation of p27Kip1 Promotes Binding to 14-3-3 and Cytoplasmic Localization. J. Biol. Chem. 277: 28706-28713 [Abstract] [Full Text]  
  • Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., Seelig, S., Arteaga, C. L. (2002). Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action. Cancer Res. 62: 4132-4141 [Abstract] [Full Text]  
  • Munster, P. N., Marchion, D. C., Basso, A. D., Rosen, N. (2002). Degradation of HER2 by Ansamycins Induces Growth Arrest and Apoptosis in Cells with HER2 Overexpression via a HER3, Phosphatidylinositol 3'-Kinase-AKT-dependent Pathway. Cancer Res. 62: 3132-3137 [Abstract] [Full Text]  
  • Motoyama, A. B., Hynes, N. E., Lane, H. A. (2002). The Efficacy of ErbB Receptor-targeted Anticancer Therapeutics Is Influenced by the Availability of Epidermal Growth Factor-related Peptides. Cancer Res. 62: 3151-3158 [Abstract] [Full Text]  
  • Ciarallo, S., Subramaniam, V., Hung, W., Lee, J.-H., Kotchetkov, R., Sandhu, C., Milic, A., Slingerland, J. M. (2002). Altered p27Kip1 Phosphorylation, Localization, and Function in Human Epithelial Cells Resistant to Transforming Growth Factor {beta}-Mediated G1 Arrest. Mol. Cell. Biol. 22: 2993-3002 [Abstract] [Full Text]  
  • Muraoka, R. S., Lenferink, A. E. G., Law, B., Hamilton, E., Brantley, D. M., Roebuck, L. R., Arteaga, C. L. (2002). ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells. Mol. Cell. Biol. 22: 2204-2219 [Abstract] [Full Text]  
  • Nahta, R., Iglehart, J. D., Kempkes, B., Schmidt, E. V. (2002). Rate-limiting Effects of Cyclin D1 in Transformation by ErbB2 Predicts Synergy between Herceptin and Flavopiridol. Cancer Res. 62: 2267-2271 [Abstract] [Full Text]  
  • Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., Pollak, M. (2001). Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). JNCI J Natl Cancer Inst 93: 1852-1857 [Abstract] [Full Text]  
  • Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., Arteaga, C. L. (2001). Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2)-overexpressing Breast Cancer Cells in Vitro and in Vivo. Cancer Res. 61: 8887-8895 [Abstract] [Full Text]  
  • Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., Gilmer, T. M. (2001). The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo. Molecular Cancer Therapeutics 1: 85-94 [Abstract] [Full Text]  
  • Murillo, H., Huang, H., Schmidt, L. J., Smith, D. I., Tindall, D. J. (2001). Role of PI3K Signaling in Survival and Progression of LNCaP Prostate Cancer Cells to the Androgen Refractory State. Endocrinology 142: 4795-4805 [Abstract] [Full Text]  
  • Lapointe, J., Labrie, C. (2001). Role of the Cyclin-Dependent Kinase Inhibitor p27Kip1 in Androgen-Induced Inhibition of CAMA-1 Breast Cancer Cell Proliferation. Endocrinology 142: 4331-4338 [Abstract] [Full Text]  
  • Lenferink, A. E. G., Busse, D., Flanagan, W. M., Yakes, F. M., Arteaga, C. L. (2001). ErbB2/neu Kinase Modulates Cellular p27Kip1 and Cyclin D1 through Multiple Signaling Pathways. Cancer Res. 61: 6583-6591 [Abstract] [Full Text]  
  • Chow, N.-H., Chan, S.-H., Tzai, T.-S., Ho, C.-L., Liu, H.-S. (2001). Expression Profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder. Clin. Cancer Res. 7: 1957-1962 [Abstract] [Full Text]  
  • Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J. (2001). Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Res. 61: 4744-4749 [Abstract] [Full Text]  
  • Zhang, X.-Q., Lee, M.-S., Zelivianski, S., Lin, M.-F. (2001). Characterization of a Prostate-specific Tyrosine Phosphatase by Mutagenesis and Expression in Human Prostate Cancer Cells. J. Biol. Chem. 276: 2544-2550 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»